Rhoen Klinikum AG (RHK) Given a €25.00 Price Target at S&P Global
RHK has been the subject of a number of other reports. Warburg Research set a €26.00 ($30.23) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Thursday, August 3rd. Independent Research GmbH set a €28.00 ($32.56) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Monday, August 14th. Commerzbank Ag set a €25.00 ($29.07) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Monday, September 18th. DZ Bank AG restated a sell rating on shares of Rhoen Klinikum AG in a research note on Tuesday, August 29th. Finally, Berenberg Bank set a €26.50 ($30.81) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Monday, August 7th. Four research analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. The stock has a consensus rating of Hold and an average price target of €24.49 ($28.48).
Shares of Rhoen Klinikum AG (ETR RHK) traded down €0.05 ($0.06) during trading hours on Friday, hitting €30.28 ($35.21). The stock had a trading volume of 50,307 shares, compared to its average volume of 71,176. Rhoen Klinikum AG has a 52 week low of €22.66 ($26.35) and a 52 week high of €30.65 ($35.64).
Rhoen Klinikum AG Company Profile
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services in the areas of cardiological and coronary diseases, neurological disorders, oncology, lung diseases, and orthopedic and accident surgeries; rehabilitation services; and thoracic, pulmonary and vascular diseases, tumors, heart conditions, and nervous and skeletal system diseases.
Receive News & Ratings for Rhoen Klinikum AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum AG and related companies with Analyst Ratings Network's FREE daily email newsletter.